| 2026-03-10 | -27.0% | legal | SEC EDGAR | NXGL 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-03-10 | -27.0% | earnings | Stock Titan | NEXGEL grabs Celularity biomaterials in move expected to turn a profit - Stock Titan |
| 2026-03-10 | -27.0% | M&A | GlobeNewswire | NEXGEL Signs Definitive Agreement to License and Acquire - GlobeNewswire |
| 2026-03-10 | -27.0% | M&A | TipRanks | NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks |
| 2023-03-27 | -20.4% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2024-10-10 | +20.4% | earnings | Seeking Alpha | NEXGEL reports 133% increase in prelim revenue for Q3 |
| 2024-10-10 | +20.4% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2026-04-22 | -18.5% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | NXGL (NexGel Inc) shares fall over 15 percent after Q4 2025 EPS loss lands far below analyst consensus estimates. - Expert Verified Trades - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-11-11 | -15.8% | earnings | Seeking Alpha | NEXGEL GAAP EPS of -$0.08, revenue of $2.93M |
| 2025-08-01 | +15.7% | news | Seeking Alpha | NEXGEL announces $950,000 registered direct offering |
| 2025-08-01 | +15.7% | legal | SEC EDGAR | NXGL 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-01-02 | -15.1% | executive | Seeking Alpha | NEXGEL appoints Joseph McGuire as CFO |
| 2025-11-12 | -15.1% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript |
| 2025-11-12 | -15.1% | legal | SEC EDGAR | NXGL 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-14 | -14.7% | earnings | Seeking Alpha | NEXGEL GAAP EPS of -$0.09 misses by $0.04, revenue of $2.81M misses by $0.27M |
| 2025-05-14 | -14.7% | earnings | Seeking Alpha | NEXGEL maintains $13M revenue target for 2025 while advancing contract manufacturing and consumer brands |
| 2025-05-14 | -14.7% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript |
| 2022-03-21 | +14.1% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2024-02-21 | +13.5% | legal | SEC EDGAR | NXGL 8-K: 1.01, 8.01 (SEC Filing) |
| 2022-12-07 | +12.7% | legal | SEC EDGAR | NXGL 8-K: 8.01 and (SEC Filing) |
| 2024-04-01 | -12.0% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript |
| 2024-04-01 | -12.0% | earnings | Seeking Alpha | NEXGEL reports Q4 results |
| 2024-04-01 | -12.0% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2026-04-09 | -10.9% | earnings | GuruFocus.com | NexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... |
| 2026-04-09 | -10.9% | news | Cổng thông tin điện tử Tỉnh Sơn La | Will NexGel (NXGL) Stock Grow in 2026 | Price at $0.60, Down 5.90% - Insider Info - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-08-12 | -10.8% | earnings | Seeking Alpha | NEXGEL targets $13M revenue and positive EBITDA for 2025 as contract manufacturing and branded products surge |
| 2025-08-12 | -10.8% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript |
| 2025-08-12 | -10.8% | earnings | Seeking Alpha | NEXGEL GAAP EPS of -$0.09 misses by $0.02, revenue of $2.88M misses by $0.2M |
| 2025-08-12 | -10.8% | legal | SEC EDGAR | NXGL 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-15 | -10.4% | earnings | Seeking Alpha | NEXGEL GAAP EPS of -$0.14, revenue of $1.44M |
| 2024-08-15 | -10.4% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript |
| 2025-03-24 | +10.2% | earnings | Seeking Alpha | NEXGEL targets $13M revenue in 2025 amid product and partnership expansion |
| 2025-03-24 | +10.2% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript |
| 2025-03-24 | +10.2% | earnings | Seeking Alpha | NEXGEL reports Q4 results |
| 2025-03-24 | +10.2% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2026-04-05 | +9.5% | news | Seeking Alpha | Quant snapshot: Delta Air Lines leads top-rated names as Byrna Technologies, Simulations Plus lag |
| 2026-02-10 | +8.8% | earnings | Quiver Quantitative | NEXGEL, Inc. Announces $1.797 Million Financing for Potential Acquisition in Q1 2026 - Quiver Quantitative |
| 2026-02-10 | +8.8% | M&A | Stock Titan | NEXGEL gets $1.8M, investor weighs extra $14.9M deal pending due diligence - Stock Titan |
| 2025-05-13 | -8.6% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2025-11-24 | +8.0% | legal | SEC EDGAR | NXGL 8-K: 8.01 and (SEC Filing) |
| 2025-01-06 | -7.8% | legal | SEC EDGAR | NXGL 8-K: 1.01, 3.02, 5.02, 8.01 (SEC Filing) |
| 2021-12-27 | -7.7% | legal | SEC EDGAR | NXGL 8-K: 1.01, 3.01 (SEC Filing) |
| 2024-03-15 | +7.7% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-04-01 | -7.5% | legal | Stock Titan | NXGL SEC Filings - Nexgel Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2023-12-12 | -7.4% | legal | SEC EDGAR | NXGL 8-K: 5.02 and (SEC Filing) |
| 2025-03-19 | -7.1% | news | Stock Titan | Healthcare Innovator NEXGEL Announces 2024 Financial Results Date: Key Growth Metrics Expected - Stock Titan |
| 2026-01-30 | -7.0% | legal | SEC EDGAR | NXGL 8-K: 5.02 and (SEC Filing) |
| 2026-04-15 | +6.7% | news | GlobeNewswire | NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction |
| 2026-04-15 | +6.7% | news | Cổng thông tin điện tử Tỉnh Sơn La | NexGel (NXGL) Stock: Why Institutions Own It (Leaps) 2026-04-15 - High Interest Stocks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2022-09-01 | -6.4% | analyst | TradingView | NXGL Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-08-14 | -6.3% | legal | SEC EDGAR | NXGL 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-03-17 | -6.0% | analyst | marketscreener.com | NEXGEL, Inc.: Target Price Consensus and Analysts Recommendations | NXGL | US65344E1073 - marketscreener.com |
| 2024-11-12 | -5.7% | legal | SEC EDGAR | NXGL 8-K: 1.01, 8.01 (SEC Filing) |
| 2024-08-14 | -5.3% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2023-12-05 | -5.1% | M&A | Seeking Alpha | NEXGEL expands health and wellness portfolio with acquisition of psoriasis skincare line |
| 2023-12-05 | -5.1% | legal | SEC EDGAR | NXGL 8-K: 1.01, 2.01, 8.01 (SEC Filing) |
| 2024-11-14 | -5.1% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript |
| 2024-11-14 | -5.1% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2024-01-16 | -5.0% | legal | SEC EDGAR | NXGL 8-K: 5.02 and (SEC Filing) |
| 2025-04-25 | -4.9% | news | Stock Titan | NXGL Stock Price, News & Analysis - Stock Titan |
| 2024-05-20 | -4.8% | legal | SEC EDGAR | NXGL 8-K: 1.01, 2.01, 3.02, 8.01 (SEC Filing) |
| 2026-01-31 | -4.7% | earnings | simplywall.st | NEXGEL, Inc.'s (NASDAQ:NXGL) Profit Outlook - simplywall.st |
| 2024-08-12 | -4.5% | news | Seeking Alpha | NEXGEL announces $1.1M registered direct offering led by insiders |
| 2026-03-25 | +3.9% | news | GlobeNewswire | NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st |
| 2026-03-25 | +3.9% | earnings | Stock Titan | NEXGEL sets March 31 earnings release, 4:30 p.m. ET call - Stock Titan |
| 2025-04-07 | +3.7% | executive | Stock Titan | NEXGEL Reveals Growth Strategy: CEO Set for Major Investor Presentation in Las Vegas - Stock Titan |
| 2022-08-10 | +3.4% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2026-03-12 | +3.2% | M&A | GlobeNewswire | NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products |
| 2026-03-12 | +3.2% | analyst | GuruFocus | NexGel (NXGL) Price Target Lowered by Maxim Group | NXGL Stock N - GuruFocus |
| 2026-03-12 | +3.2% | earnings | Stock Titan | Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan |
| 2026-03-12 | +3.2% | news | Stock Titan | Asymmetry Point LP holds 610,000 shares of NexGel (NXGL) reporting 7.49% stake - Stock Titan |
| 2026-03-12 | +3.2% | expansion | GlobeNewswire | NEXGEL Announces Consideration Terms of Agreement to - GlobeNewswire |
| 2026-01-07 | -3.1% | legal | SEC EDGAR | NXGL 8-K: 5.02 and (SEC Filing) |
| 2022-05-12 | -3.0% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2023-12-29 | +2.7% | legal | SEC EDGAR | NXGL 8-K: 1.01, 3.02, 5.02 (SEC Filing) |
| 2023-01-06 | -2.6% | legal | SEC EDGAR | NXGL 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-08-05 | -2.6% | legal | SEC EDGAR | NXGL 8-K: 5.02, 8.01 (SEC Filing) |
| 2024-11-11 | -2.6% | news | Seeking Alpha | NEXGEL announces $2M registered direct offering |
| 2025-06-20 | -2.5% | legal | SEC EDGAR | NXGL 8-K: 5.02, 5.07 (SEC Filing) |
| 2023-11-13 | +2.2% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2023-03-23 | +2.1% | legal | SEC EDGAR | NXGL 8-K: 8.01 and (SEC Filing) |
| 2022-11-16 | -2.0% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for NexGel (NXGL) - Zacks Investment Research |
| 2022-11-08 | -2.0% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2023-01-17 | -1.8% | legal | SEC EDGAR | NXGL 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-04-08 | -1.7% | news | GlobeNewswire | NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction |
| 2026-04-08 | -1.7% | news | GlobeNewswire | NEXGEL Reschedules Shareholder Update Conference Call to - GlobeNewswire |
| 2026-04-08 | -1.7% | news | Stock Titan | NEXGEL drops prior financing plan, pushes Celularity update to April 15 - Stock Titan |
| 2024-11-13 | +1.5% | earnings | Seeking Alpha | NEXGEL GAAP EPS of -$0.11 misses by $0.01, revenue of $2.94M beats by $0.09M |
| 2025-09-25 | -0.9% | legal | Stock Titan | NXGL SEC Filings - Nexgel Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-03-31 | -0.9% | news | GlobeNewswire | NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity |
| 2026-03-31 | -0.9% | earnings | Quiver Quantitative | NexGel (NXGL) Releases Q4 2025 Earnings: Revenue Down, Losses Narrow, Cash Tight | NXGL Stock News - Quiver Quantitative |
| 2026-03-31 | -0.9% | earnings | Stock Titan | NEXGEL delays earnings call a week to add detail on Celularity deal - Stock Titan |
| 2026-04-17 | -0.9% | news | GlobeNewswire | NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET |
| 2026-04-17 | -0.9% | news | Stock Titan | Shareholders get NEXGEL's Celularity transaction update 2 days earlier - Stock Titan |
| 2026-02-11 | +0.8% | legal | SEC EDGAR | NXGL 8-K: 1.01, 2.03, 3.02, 7.01 (SEC Filing) |
| 2024-07-08 | +0.7% | earnings | Seeking Alpha | NEXGEL reports Q2 preliminary revenue and issues Q3 and Q4 guidance |
| 2024-07-08 | +0.7% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2026-04-21 | +0.4% | M&A | GlobeNewswire | NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment |
| 2026-04-21 | +0.4% | news | GlobeNewswire | Celularity Announces Closing of Transaction with NexGel |
| 2026-04-21 | +0.4% | earnings | Moby | NEXGEL, Inc. Q4 2025 Earnings Call Summary |
| 2026-04-21 | +0.4% | earnings | Seeking Alpha | NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition |
| 2026-04-21 | +0.4% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q4 2025 Earnings Call Transcript |
| 2026-04-21 | +0.4% | earnings | Seeking Alpha | NEXGEL GAAP EPS of -$0.38 misses by $0.32, revenue of $11.42M misses by $5.46M |
| 2026-04-21 | +0.4% | legal | SEC EDGAR | NXGL 8-K: 1.01, 2.01, 2.03, 3.02, 8.01 (SEC Filing) |
| 2026-04-21 | +0.4% | news | Stock Titan | A $5.5M financing gives NEXGEL 6 regenerative products and a new unit - Stock Titan |
| 2024-05-13 | -0.3% | earnings | Seeking Alpha | NEXGEL, Inc. (NXGL) Q1 2024 Earnings Call Transcript |
| 2024-05-13 | -0.3% | earnings | Seeking Alpha | NEXGEL reports EPS of -$0.14, revenue of $1.27M |
| 2024-05-13 | -0.3% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2023-05-15 | +0.3% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2025-01-22 | -0.2% | legal | SEC EDGAR | NXGL 8-K: 2.02 and (SEC Filing) |
| 2024-08-13 | +0.2% | legal | SEC EDGAR | NXGL 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-02-04 | +0.1% | earnings | simplywall.st | The Market Doesn't Like What It Sees From NEXGEL, Inc.'s (NASDAQ:NXGL) Revenues Yet As Shares Tumble 32% - simplywall.st |
| 2026-04-24 | — | news | Stock Titan | NexGel (NASDAQ: NXGL) warned by Nasdaq over sub-$1 share price and delisting risk - Stock Titan |